CCL2 and prostate cancer: In another study, inhibition of ENO1 by HuL227 halted inflammation-induced migration of PC-3 prostate cancer cells and reduced CCL2 or TGFβ-enhanced migration of PC-3 and DU145 prostate cancer cells [124].